---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-000716"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2023-02-10T23:59:59+00:00"
generated_at: "2026-06-19T17:48:23.662425+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Sunshine Biopharma signs research agreement with Jewish General Hospital for Adva-27a anticancer compound

## Summary
- 3-year agreement to advance Adva-27a through IND-enabling studies; JGH paid fair market value for services.
- Sunshine retains exclusive ownership of all improvements and research results; JGH receives 3% royalty for 20 years on net revenues from IP.
- Research led by Dr. Gerald Batist, Head of Oncology at JGH and Director of the McGill Centre for Translational Research in Cancer.
- If results are conclusive, parties will negotiate terms to conduct a Phase I clinical trial.

## SEC filing metadata
- accession: 0001683168-23-000716
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2023-02-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316823000716/0001683168-23-000716-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316823000716/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-000716
- JSON: https://secwatch.observer/filing/0001683168-23-000716.json
- Plain text: https://secwatch.observer/filing/0001683168-23-000716.txt

## Key facts
- Material Agreements
  Sunshine Biopharma Inc. entered into Research Agreement with Sir Mortimer B. Davis Jewish General Hospital valued at 3% royalty (effective 2023-02-07).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Sir Mortimer B. Davis Jewish General Hospital
  - Value: 3% royalty
  - Effective: 2023-02-07
  source text: On February 7, 2023, Sunshine Biopharma, Inc. (the “Company”) received a duly executed research agreement (the “Research Agreement”) with Sir Mortimer B. Davis Jewish General Hospital, a McGill University Health Center hospital located in Montreal, Quebec, Canada (“JGH”) in connection with the Company’s Adva-27a anticancer compound.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316823000716/0001683168-23-000716-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.